Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BDM E

Next Previous
X
Search
Drug Profile

BDM E

Alternative Names: Ala-glu-asp-gly - BioDiem; Alanyl glutamyl aspartyl glycine - BioDiem; BDM-E; Epitalon - BioDiem; Epitalon tetrapeptide - BioDiem; Epithalon - BioDiem; Epithalon tetrapeptide - BioDiem

Latest Information Update: 31 Mar 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Institute of Bioregulation and Gerontology
  • Developer BioDiem; Monash University; University of Cambridge; University of Wisconsin at Milwaukee
  • Class Eye disorder therapies; Oligopeptides; Small molecules
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa
  • New Molecular Entity Yes
  • Available For Licensing Yes - Retinitis pigmentosa

Highest Development Phases

  • Phase I/II Diabetic macular oedema
  • No development reported Age-related macular degeneration; Retinitis pigmentosa; Retinopathy of prematurity

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in Australia (SC, Injection)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetic-macular-oedema in Australia (SC, Injection)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetic-macular-oedema in United Kingdom (SC, Injection)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top